Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.25.0.1
Earnings (Loss) Per Common Share (Tables)
6 Months Ended
Dec. 31, 2024
Earnings (Loss) Per Common Share  
Schedule of Components Used in Determining Earnings (Loss) Per Common Share

Three Months Ended

Six Months Ended

December 31, 

December 31, 

    

2024

    

2023

2024

    

2023

Basic and diluted numerator:

Net loss from continuing operations

$

(4,364)

$

(4,488)

$

(8,353)

$

(9,562)

Net loss from discontinued operations

$

$

(3,723)

$

$

(4,395)

Net loss - total

$

(4,364)

$

(8,211)

$

(8,353)

$

(13,957)

Basic and diluted denominator:

Weighted-average common shares outstanding

 

9,132

 

1,856

 

8,880

 

1,525

 

 

 

 

Per share amount - continuing operations

$

(0.48)

$

(2.42)

$

(0.94)

$

(6.27)

Per share amount - discontinued operations

$

$

(2.00)

$

$

(2.88)

Per share amount - total

$

(0.48)

$

(4.42)

$

(0.94)

$

(9.15)

Schedule of Shares Issuable Which Could Potentially Dilute Future Earnings

December 31, 

    

2024

    

2023

(in thousands)

Stock options

 

1,058

 

36

Restricted stock units

    

12

    

3

Warrants

11,521

5,339

AstralBio Exclusive License Agreement

246

Shares excluded from the calculation of diluted loss per share

 

12,837

 

5,378